Canaccord downgraded Nevro to Hold from Buy with a $23 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NVRO:
- Citi entering 2024 ‘cautiously optimistic’ on U.S. MedTech companies
- Nevro Announces Acquisition of Vyrsa™ Technologies
- Nevro’s SCS system delivers long-term relief with spinal cord stimulation
- NeuroPace price target raised to $8 from $6 at Morgan Stanley
- Nevro price target lowered to $30 from $57 at Canaccord